ORASIS PHARMACEUTICALS ANNOUNCES AUSTRALIA SUBMISSION OF A NEW DRUG APPLICATION FOR BESKA FOR THE TREATMENT OF PRESBYOPIA
Submission of New Drug Application (NDA) in Australia by Aspen Pharmacare Australia (Aspen Australia) marks the first ex-U.S. regulatory submission (known as QLOSI® in the U.S.) PONTE VEDRA, Fla., July 15, 2026 /PRNewswire/ -- Orasis Pharmaceuticals and Aspen Australia announced that...
Submission of New Drug Application (NDA) in Australia by Aspen Pharmacare Australia (Aspen Australia) marks the first ex-U.S. regulatory submission (known as QLOSI® in the U.S.) PONTE VEDRA, Fla., July 15, 2026 /PRNewswire/ -- Orasis Pharmaceuticals and Aspen Australia announced that...
Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.